keyword
MENU ▼
Read by QxMD icon Read
search

overall survival breast cancer

keyword
https://www.readbyqxmd.com/read/28822996/examining-bias-in-studies-of-statin-treatment-and-survival-in-patients-with-cancer
#1
Louise Emilsson, Xabier García-Albéniz, Roger W Logan, Ellen C Caniglia, Mette Kalager, Miguel A Hernán
Importance: Patients with cancer who use statins appear to have a substantially better survival than nonusers in observational studies. However, this inverse association between statin use and mortality may be due to selection bias and immortal-time bias. Objective: To emulate a randomized trial of statin therapy initiation that is free of selection bias and immortal-time bias. Design, Setting, and Participants: We used observational data on 17 372 patients with cancer from the Surveillance, Epidemiology, and End Results (SEER)-Medicare database (2007-2009) with complete follow-up until 2011...
August 20, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28822397/outcomes-after-mastectomy-and-lumpectomy-in-octogenarians-and-nonagenarians-with-early-stage-breast-cancer
#2
Amelia Y Merrill, Doris R Brown, Heidi D Klepin, Edward A Levine, Marissa Howard-Mcnatt
Prospective studies have shown equal outcomes after mastectomy or breast conservation in patients with invasive breast cancer; however, many of these studies excluded elderly patients. We identified patients in their eighties and nineties with clinical stage 0 to II breast cancer undergoing mastectomy or lumpectomy with or without radiation from the prospective sentinel lymph node database at Wake Forest Baptist Health and analyzed their treatment and survival. Of 92 patients, 24 (26.1%) underwent mastectomy, 22 (23...
August 1, 2017: American Surgeon
https://www.readbyqxmd.com/read/28822389/mammographic-screening-at-age-40-or-45-what-difference-does-it-make-the-potential-impact-of-american-cancer-society-mammography-screening-guidelines
#3
Crystal E Fancher, Anthony Scott, Ahkeel Allen, Paul Dale
this is a 10-year retrospective chart review evaluating the potential impact of the most recent American Cancer Society mammography screening guidelines which excludes female patients aged 40 to 44 years from routine annual screening mammography. Instead they recommend screening mammography starting at age 45 with the option to begin screening earlier if the patient desires. The institutional cancer registry was systematically searched to identify all women aged 40 to 44 years treated for breast cancer over a 10-year period...
August 1, 2017: American Surgeon
https://www.readbyqxmd.com/read/28822078/prognostic-implication-of-the-primary-tumor-location-in-early-stage-breast-cancer-focus-on-lower-inner-zone
#4
Jiqiao Yang, Shenli Tang, Yuting Zhou, Juanjuan Qiu, Juying Zhang, Sui Zhu, Qing Lv
BACKGROUND: The aim of this study was to investigate the prognostic significance of tumor location of lower inner zone (LIZ) on the survival of patients with early-stage breast cancer. METHODS: We retrospectively identified 961 breast cancer patients from Jan 2000 to Apr 2016 from hospital database. We evaluated overall survival (OS) and disease-free survival (DFS) in patients with tumors in and outside LIZ. Subgroup analyses were performed according to clinicopathological characteristics and treatment strategies...
August 18, 2017: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/28822007/brca1-like-profile-is-not-significantly-associated-with-survival-benefit-of-non-myeloablative-intensified-chemotherapy-in-the-gain-randomized-controlled-trial
#5
A G J van Rossum, P C Schouten, K E Weber, V Nekljudova, C Denkert, C Solbach, C H Köhne, C Thomssen, H Forstbauer, G Hoffmann, A Kohls, S Schmatloch, C Schem, G von Minckwitz, T Karn, V J Möbus, S C Linn, S Loibl, F Marmé
PURPOSE: The BRCA1-like profile identifies tumors with a defect in homologous recombination due to inactivation of BRCA1. This profile has been shown to predict which stage III breast cancer patients benefit from myeloablative, DNA double-strand-break-inducing chemotherapy. We tested the predictive potential of the BRCA1-like profile for adjuvant non-myeloablative, intensified dose-dense chemotherapy in the GAIN trial. METHODS: Lymph node positive breast cancer patients were randomized to 3 × 3 dose-dense cycles of intensified epirubicin, paclitaxel, and cyclophosphamide (ETC) or 4 cycles concurrent epirubicin and cyclophosphamide followed by 10 cycles of weekly paclitaxel combined with 4 cycles capecitabine (EC-TX)...
August 18, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28820959/takinib-a-selective-tak1-inhibitor-broadens-the-therapeutic-efficacy-of-tnf-%C3%AE-inhibition-for-cancer-and-autoimmune-disease
#6
Juliane Totzke, Deepak Gurbani, Rene Raphemot, Philip F Hughes, Khaldon Bodoor, David A Carlson, David R Loiselle, Asim K Bera, Liesl S Eibschutz, Marisha M Perkins, Amber L Eubanks, Phillip L Campbell, David A Fox, Kenneth D Westover, Timothy A J Haystead, Emily R Derbyshire
Tumor necrosis factor alpha (TNF-α) has both positive and negative roles in human disease. In certain cancers, TNF-α is infused locally to promote tumor regression, but dose-limiting inflammatory effects limit broader utility. In autoimmune disease, anti-TNF-α antibodies control inflammation in most patients, but these benefits are offset during chronic treatment. TAK1 acts as a key mediator between survival and cell death in TNF-α-mediated signaling. Here, we describe Takinib, a potent and selective TAK1 inhibitor that induces apoptosis following TNF-α stimulation in cell models of rheumatoid arthritis and metastatic breast cancer...
August 17, 2017: Cell Chemical Biology
https://www.readbyqxmd.com/read/28819769/disparities-in-breast-cancer-private-patients-have-better-outcomes-than-public-patients
#7
W C Coetzee, J P Apffelstaedt, T Zeeman, M Du Plessis
INTRODUCTION: Different outcomes in breast cancer have been reported for low and high socio-economic groups. We present data quantifying disparities between South African public and private patients. METHODS: Records of 240 consecutive patients treated in 2008 in a public versus 97 patients in a private health facility were reviewed for demographic and oncologic data. RESULTS: The average of patients was 56.2 versus 51.9 years (p = 0.032)...
August 17, 2017: World Journal of Surgery
https://www.readbyqxmd.com/read/28819438/elevated-expression-of-derlin-1-associates-with-unfavorable-survival-time-of-squamous-cell-carcinoma-of-the-head-and-neck-and-promotes-its-malignance
#8
Leiming Pi, Gangcai Zhu, Li She, Ming Wei, Guancheng Liu, Changhan Chen, Di Hu, Fusen Peng, Haolei Tan, Yong Liu, Donghai Huang, Yongquan Tian, Xin Zhang
Derlin-1 is over-expressed to function as an oncoprotein in breast, lung and colon cancers. However, the implications of Derlin-1 involved in squamous cell carcinoma of the head and neck (SCCHN) remain unknown. This study aims to investigate the effects of Derlin-1 expression on SCCHN tissues and cells. The potential mechanism of Derlin-1 regulating SCCHN cell proliferation, apoptosis and metastasis was also indicated in this work. Western blot and immunohistochemistry (IHC) assays showed that Derlin-1 was over-expressed in 114 SCCHN samples and five SCCHN cell lines...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28819403/impact-of-statin-use-on-outcomes-in-triple-negative-breast-cancer
#9
Simona F Shaitelman, Michael C Stauder, Pamela Allen, Sangeetha Reddy, Susan Lakoski, Bradley Atkinson, Jay Reddy, Diana Amaya, William Guerra, Naoto Ueno, Abigail Caudle, Welela Tereffe, Wendy A Woodward
Purpose: We sought to investigate if the use of HMG Co-A reductase inhibitors (statins) has an impact on outcomes among patients with triple negative breast cancer (TNBC). Methods: We reviewed the cases of women with invasive, non-metastatic TNBC, diagnosed 1997-2012. Clinical outcomes were compared based on statin use (defined as ever use during treatment vs. never use). We identified a subset of women for whom a 5-value lipid panel (5VLP) was available, including total cholesterol, low density lipoprotein, high density lipoprotein, very low density lipoprotein, and triglycerides...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28819368/lack-of-breastfeeding-history-in-parous-women-with-inflammatory-breast-cancer-predicts-poor-disease-free-survival
#10
Shane R Stecklein, Jay P Reddy, Adam R Wolfe, Mirtha S Lopez, Tamer M Fouad, Bisrat G Debeb, Naoto T Ueno, Abenaa M Brewster, Wendy A Woodward
Purpose: Breastfeeding alters the breast microenvironment, and several lines of evidence suggest the breast microenvironment contributes to the clinical phenotype of inflammatory breast cancer. We investigated breastfeeding history as a modifier of locoregional recurrence (LRR), distant metastasis (DM), disease-free survival (DFS), and overall survival (OS) in parous women with inflammatory breast cancer. Methods: Parous women with inflammatory breast cancer were identified from a prospective registry at The University of Texas MD Anderson Cancer Center...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28818493/progression-free-survival-and-time-to-progression-as-real-surrogate-end-points-for-overall-survival%C3%A2-in-advanced-breast-cancer-a-meta-analysis-of-37-trials
#11
Ling Li, Zhanyu Pan
BACKGROUND: Progression-free survival (PFS) and time to progression (TTP) have been reported to correlate with overall survival (OS) in several cancer types. To our knowledge, however, the correlation between them is unclear. METHODS: A literature-based meta-analysis was performed to assess whether PFS and TTP can be considered reliable surrogate end points for OS in a phase 3 clinical trial of advanced breast cancer (ABC). The median hazard ratios of PFS/TTP and OS were analyzed by determining their nonparametric Spearman rank correlation coefficients (Rs)...
July 25, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28818465/girdin-protein-expression-is-associated-with-poor-prognosis-in-patients-with-invasive-breast-cancer
#12
Jong-Sun Choi, Kyung Hee Kim, Ensel Oh, Young Kee Shin, Jinwon Seo, Seok-Hyung Kim, Sarah Park, Yoon-La Choi
Girdin is an actin-binding Akt substrate that is an integral component of the PI3K/Akt signalling pathway. However, the clinicopathological significance of Girdin expression in breast cancer has not been clarified. The purpose of this study was to characterise the clinicopathological implication of Girdin expression in breast cancer. Immunohistochemistry-based protein expression analyses of 892 human breast cancer tissues showed that Girdin was expressed in 289 (32.4%) cases. Girdin expression was significantly associated with larger tumour size, frequent lymph node invasion, advanced cancer stage, and expression of oestrogen and progesterone receptors...
August 14, 2017: Pathology
https://www.readbyqxmd.com/read/28815913/metastatic-triple-negative-breast-cancer-optimizing-treatment-options-new-and-emerging-targeted-therapies
#13
REVIEW
Parham Khosravi-Shahi, Luis Cabezón-Gutiérrez, Sara Custodio-Cabello
Triple negative breast cancer (TNBC) is a heterogeneous disease, not only on the molecular level, but also on the pathologic and clinical levels. It also has a distinct epidemiology. TNBCs are frequently of high histologic grade, typically more aggressive and difficult to treat than hormone receptor-positive tumors, and they are associated with a higher risk of early relapse with visceral metastasis after surgery, chemotherapy and/or radiotherapy. The lack of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 expression precludes the use of targeted therapies in advanced stages, and the only approved systemic treatment option is chemotherapy with or without bevacizumab...
August 16, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28814897/discordance-of-the-estrogen-receptor-and-her-2-neu-in-breast-cancer-from-primary-lesion-to-first-and-second-metastatic-site
#14
Elyse E Lower, Shagufta Khan, Diane Kennedy, Robert P Baughman
BACKGROUND: Hormone receptor and HER-2/neu discordance between the primary lesion and first metastasis has been reported. This study was performed to determine further biomarker discordance rates between the first and subsequent metastatic breast cancer lesions. METHODS: We performed a retrospective review of paired biomarkers from primary breast cancers compared to first reported and subsequent metastases from 103 patients with breast cancer. The estrogen receptor (ER), progesterone receptor (PR), and HER-2/neu status were reported at all three time points...
2017: Breast Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/28814868/nano-sized-cytochrome-p450-3a4-inhibitors-to-block-hepatic-metabolism-of-docetaxel
#15
Marion Paolini, Laurence Poul, Céline Berjaud, Matthieu Germain, Audrey Darmon, Maxime Bergère, Agnès Pottier, Laurent Levy, Eric Vibert
Most drugs are metabolized by hepatic cytochrome P450 3A4 (CYP3A4), resulting in their reduced bioavailability. In this study, we present the design and evaluation of bio-compatible nanocarriers trapping a natural CYP3A4-inhibiting compound. Our aim in using nanocarriers was to target the natural CYP3A4-inhibiting agent to hepatic CYP3A4 and leave drug-metabolizing enzymes in other organs undisturbed. In the design of such nanocarriers, we took advantage of the nonspecific accumulation of small nanoparticles in the liver...
2017: International Journal of Nanomedicine
https://www.readbyqxmd.com/read/28814544/direct-detection-of-early-stage-cancers-using-circulating-tumor-dna
#16
Jillian Phallen, Mark Sausen, Vilmos Adleff, Alessandro Leal, Carolyn Hruban, James White, Valsamo Anagnostou, Jacob Fiksel, Stephen Cristiano, Eniko Papp, Savannah Speir, Thomas Reinert, Mai-Britt Worm Orntoft, Brian D Woodward, Derek Murphy, Sonya Parpart-Li, David Riley, Monica Nesselbush, Naomi Sengamalay, Andrew Georgiadis, Qing Kay Li, Mogens Rørbæk Madsen, Frank Viborg Mortensen, Joost Huiskens, Cornelis Punt, Nicole van Grieken, Remond Fijneman, Gerrit Meijer, Hatim Husain, Robert B Scharpf, Luis A Diaz, Siân Jones, Sam Angiuoli, Torben Ørntoft, Hans Jørgen Nielsen, Claus Lindbjerg Andersen, Victor E Velculescu
Early detection and intervention are likely to be the most effective means for reducing morbidity and mortality of human cancer. However, development of methods for noninvasive detection of early-stage tumors has remained a challenge. We have developed an approach called targeted error correction sequencing (TEC-Seq) that allows ultrasensitive direct evaluation of sequence changes in circulating cell-free DNA using massively parallel sequencing. We have used this approach to examine 58 cancer-related genes encompassing 81 kb...
August 16, 2017: Science Translational Medicine
https://www.readbyqxmd.com/read/28811593/prognostic-value-of-routine-laboratory-variables-in-prediction-of-breast-cancer-recurrence
#17
Zhu Zhu, Ling Li, Zhong Ye, Tong Fu, Ye Du, Aiping Shi, Di Wu, Ke Li, Yifan Zhu, Chun Wang, Zhimin Fan
The prognostic value of routine laboratory variables in breast cancer has been largely overlooked. Based on laboratory tests commonly performed in clinical practice, we aimed to develop a new model to predict disease free survival (DFS) after surgical removal of primary breast cancer. In a cohort of 1,596 breast cancer patients, we analyzed the associations of 33 laboratory variables with patient DFS. Based on 3 significant laboratory variables (hemoglobin, alkaline phosphatase, and international normalized ratio), together with important demographic and clinical variables, we developed a prognostic model, achieving the area under the curve of 0...
August 15, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28810875/role-of-iqgap3-in-metastasis-and-epithelial-mesenchymal-transition-in-human-hepatocellular-carcinoma
#18
Yongjie Shi, Nan Qin, Qiang Zhou, Yanqiu Chen, Sicong Huang, Bo Chen, Gang Shen, Hongyun Jia
BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most lethal cancers worldwide owing to its high rates of metastasis and recurrence. The oncogene IQ motif-containing GTPase activating protein 3 (IQGAP3) is ubiquitously overexpressed in several human cancers, including liver, ovary, lung, large intestine, gastric, bone marrow, and breast malignancies and is involved in the invasion and metastasis of cancer cells. Therefore, we aimed to determine the biological role and molecular mechanism of IQGAP3 in HCC...
August 15, 2017: Journal of Translational Medicine
https://www.readbyqxmd.com/read/28810291/-correlation-between-extranodal-invasion-in-axillary-lymph-node-metastasis-and-prognosis-of-breast-cancer-patients
#19
L L Zhang, L Ma, C Z Geng, Y Jia, X L Wang, Y P Liu
Objective: To investigate the significance of extranodal extension of axillary lymph nodes (ALN-ENE) metastases in post-operative primary invasive breast carcinoma of non-specific type. Methods: Six hundred and thirty-eight invasive breast cancer cases confirmed by postoperative pathological examination were collected from January 2006 to December 2008. The relationship of lymph node metastases and ALN-ENE with other lymph node parameters and patient outcome was analyzed. Results: Among 638 cases, 263 (41.2%) showed axillary lymph node metastases...
August 8, 2017: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
https://www.readbyqxmd.com/read/28810186/the-efficacy-of-lapatinib-and-capecitabine-in-her-2-positive-breast-cancer-with-brain-metastases-a-systematic-review-and-pooled-analysis
#20
REVIEW
Fausto Petrelli, Michele Ghidini, Veronica Lonati, Gianluca Tomasello, Karen Borgonovo, Mara Ghilardi, Mary Cabiddu, Sandro Barni
INTRODUCTION: Breast cancer (BC) with HER-2/neu overexpression or amplification (HER-2+) is associated with a higher prevalence of brain metastases (BMs) when compared to other subtypes. Among approved drugs for HER-2+ BC, lapatinib (L) is associated with single agent activity toward BMs. We conducted a systematic review to determine the efficacy of L, singly or in combination with capecitabine (C), as a treatment for HER-2+ BMs. MATERIAL AND METHODS: We searched PubMed, EMBASE, The Cochrane Library, SCOPUS, Web of Science, ClinicalTrials...
August 12, 2017: European Journal of Cancer
keyword
keyword
107111
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"